US EditionIPA Advances AI-Discovered Universal Dengue Vaccine - AI-Tech Park
Summary by AI TechPark
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
IPA Advances AI-Discovered Universal Dengue Vaccine - AI-Tech Park
Manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program. Building on its June announcements confirming the discovery and val…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
